Overview

Neoadjuvant Encorafenib, Binimetinib and Cetuximab for Patients With BRAF V600E Mutated/pMMR Localized Colorectal Cancer

Status:
Not yet recruiting

Trial end date:
2025-01-31

Target enrollment:

Participant gender:

Summary

AIO-KRK-0420 NeoBRAF is a single arm, multicenter, phase II trial with neoadjuvant encorafenib, binimetinib and cetuximab for patients with BRAF V600E mutated/pMMR localized colorectal cancer.

Phase:

Phase 2

Details

Lead Sponsor:

AIO-Studien-gGmbH

Collaborators:

Merck Serono GmbH, Germany
Pierre Fabre Pharma GmbH
Universitätsklinikum Hamburg-Eppendorf

Treatments:

Cetuximab